Advertisement

Embracing the PPAR Agonist Era of PBC Management - Episode 3

Assessing PBC Treatment Options, Determining Sequencing

Published on: 
, ,

In this video segment, Reau, Trivedi, and Hirschfield discuss the EMA opinion on obeticholic acid and its impact on discussions about second-line therapies amid the influx of new treatment options available for patients.

In recognition of the US Food and Drug Administration accelerated approval of Gilead's seladelpar (Livdelzi) and other recent evolutions in primary biliary cholangitis (PBC), the latest HCPLive Special Report spotlights a conversation between a trio of subject matter experts on the latest advancements in PBC and their implications for disease management.

A chronic and progressive autoimmune liver disease affecting intrahepatic bile ducts, common symptoms of PBC include ​​jaundice, pruritus, and fatigue. Ursodeoxycholic acid (UDCA) has long been the mainstay of treatment for PBC and continues to be the only first-line therapy. However, many patients do not respond to or are unable to tolerate UDCA, underscoring the need for more treatment options to prevent progression to cirrhosis and eventual liver failure as well as to improve symptoms most negatively impacting patients. In the past 3 months alone, the PBC treatment landscape has seen the addition of 2 new therapeutic options with the accelerated approvals of seladelpar and elafibranor, both of which are proliferator-activated receptor agonists shown to reduce alkaline phosphatase.

In the third segment of our 6-part HCPLive Special Report on the evolving landscape of PBC management, moderator Nancy Reau, MD, asks Gideon Hirschfield, PhD, MB BChir, about how the recent European Medicines Agency (EMA) opinion on obeticholic acid (OCA) has impacted discussions with his patients about second-line therapies. Acknowledging potential misinterpretation of what the EMA message meant, Hirschfield describes the importance of having multiple treatment options and delves into the complexities of sequencing therapies for PBC patients, a critical consideration given the expanding array of treatment options.

Specifically, he discusses the challenges clinicians face in making decisions about which therapies to use and in what order, especially in the context of varying patient severity and the specific mechanisms of each therapy. Ultimately, Hirschfield emphasizes the goal is to achieve the best possible outcomes by strategically combining and sequencing treatments to maximize efficacy and minimize adverse effects.

Check out the other segments in this series:

Panelists

  • Nancy Reau, MD (Moderator): associate director of solid organ transplantation and section chief of hepatology at Rush University Medical Center
  • Palak Trivedi, MD, PhD: associate professor and honorary consultant hepatologist and clinical research director for industry engagement at the University of Birmingham
  • Gideon Hirschfield, PhD, MB BChir: director of the Autoimmune Liver Disease Program at University Health Network’s Francis Family Liver Clinic and Toronto Centre for Liver Disease and Lily and Terry Horner Chair in Autoimmune Liver Disease Research at the University of Toronto

Relevant disclosures for Reau include Eiger, Gilead, AbbVie, Salix, and Intercept. Relevant disclosures for Trivedi include Bristol Myers Squibb, Gilead, Intercept, CymbaBay, and others. Relevant disclosures for Hirschfield include CymaBay, Escient, Gilead, GSK, HighTide, Intercept, Ipsen, Mirum, and Pliant.

Advertisement
Advertisement